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Identifying biological mechanisms for favorable cancer
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analysis
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Survival analyses based on the Kaplan–Meier estimate have been pervasively used to support or validate the relevance of biological
mechanisms in cancer research. Recently, with the appearance of gene expression high-throughput technologies, this kind of
analysis has been applied to tumor transcriptomics data. In a ‘bottom–up’ approach, gene-expression proﬁles that are associated
with a deregulated pathway hypothetically involved in cancer progression are ﬁrst identiﬁed and then subsequently correlated with
a survival effect, which statistically supports or requires the rejection of such a hypothesis. In this work, we propose a ‘top–down’
approach, in which the clinical outcome (survival) is the starting point that guides the identiﬁcation of deregulated biological
mechanisms in cancer by a non-hypothesis-driven iterative survival analysis. We show that the application of our novel method to a
population of ~ 2,000 breast cancer patients of the METABRIC consortium allows the identiﬁcation of several well-known cancer
mechanisms, such as ERBB4, HNF3A and TGFB pathways, and the investigation of their paradoxical dual effect. In addition, several
novel biological mechanisms are proposed as potentially involved in cancer progression. The proposed exploratory methodology
can be considered both alternative and complementary to classical 'bottom–up' approaches for validation of biological hypotheses.
We propose that our method may be used to better characterize cancer, and may therefore impact the future design of therapies
that are truly molecularly tailored to individual patients. The method, named SURCOMED, was implemented as a web-based tool,
which is publicly available at http://surcomed.vital-it.ch. R scripts are also available at http://surcomed.sourceforge.net).
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INTRODUCTION
It is increasingly accepted that cancer is not a single disease but
rather a group of molecularly distinct neoplastic disorders,1 with a
variety of underlying molecular mechanisms, morphological features,
and biomarkers that hinders the design of treatments and disease
prognosis. In addition, due to ethical limitations, most current
experimental biomedical research is carried out using either in vitro
or in vivo models. Interpreting the relevance of ﬁndings in such
models and relating them to human health remains challenging.
In the last decades, we have witnessed hundreds of oncology
studies, including those at the forefront of cancer research, where
the relevance of a given cancer-driving mechanism to human
disease is normally determined by applying the following three
steps: (1) characterize the mechanism in a biological model; (2)
identify a marker whose expression changes when the mechanism
is perturbed; and (3) show the correlation between the marker
presence and a clinical outcome in human patients. This
correlation is frequently illustrated by means of a Kaplan–Meier
plot,2 which represents a difference in survival between groups of
patients with and without the marker previously identiﬁed in the
corresponding or closest pre-clinical (animal) model.
Here we propose a novel reverse approach that can be
considered both alternative and complementary to hypothesis-
driven strategies (Figure 1). Unlike the standard approach of
identifying markers in a pre-clinical model based on a given
hypothesis and checking whether the clinical outcome in patients
supports this hypothesis, our approach searches at the tumor
transcriptomic level for relevant combinations of markers in a
population of patients based on the optimization of the
differences in the observed clinical outcome (patient survival)
between groups of patients deﬁned by these markers. In other
words, these combinations of markers, which are composed by an
arbitrary number of genes, allow the stratiﬁcation of the
population of patients into groups with an optimized difference
in the clinical outcome. Subsequently, a comparative analysis of
the resulting pro- and anti-survival patient groups for each
combination of markers allows generating hypotheses regarding
the underlying molecular mechanisms of action. The exploration
of these results for multiple combinations of survival biomarkers
allows the identiﬁcation of common mechanisms of action
associated with survival that apply to the majority of the patients,
as well as mechanisms speciﬁc to distinct groups of patients.
It is important to note here that despite the fact that the
proposed method fragments the population into groups of patients
based on both the gene expression proﬁle and clinical information,
it is not intended merely for patient classiﬁcation or for individual
patient prognosis but for hypothesis generation on cancer-driving
mechanisms. During the last years a considerable effort has been
invested to identify gene-expression signatures for better patient
characterization and prognosis. At present, besides the classical
identiﬁcation of single markers and clinical parameters, such as
tumor size, grade, cancer stage, or node status, high-throughput
technologies allow the measurement of thousands of messenger
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RNA transcripts in a single experiment and enable identiﬁcation of
multi-gene expression signatures associated with clinical outcomes.1
These multi-gene expression signatures are derived from collections
of human tumor transcriptomics data sets and can be used, for
example, to classify breast cancer tumors into subtypes reﬂecting
discrete cancer phenotypes.3–5 In general, it has been shown that
such signatures are more reliable for predicting clinical outcome
than single markers,6,7 and currently several assays are commercially
available (MammaPrint, OncotypeDX, Theros, MapQuantDX,
Mammostrat and Prosigna).
Instead, rather than attempting to ﬁnd a comprehensive and
predictive classiﬁer for patients, the methodology proposed here
is intended to assist in the identiﬁcation of cancer-driving
mechanisms of action, which may coexist in, be shared by or
distinguish groups of patients stratiﬁed by the abovementioned
gene-expression signatures or pathological markers such us ER,
PR or Her2. Moreover, the proposed methodology allows
investigating biological mechanisms with a dual effect, sometimes
protective, sometimes representing risk factors, which hinders the
interpretation of their role in cancer progression.
In summary, the algorithm, named SURCOMED (SUrvival
COmbined effect-driven cancer MEchanism Discovery),
allows the identiﬁcation of speciﬁc mechanisms of action up- or
downregulated between subgroups of a given population of
cancer patients with a signiﬁcant survival separation between
them (Figure 2). Given that the mechanisms identiﬁed by
SURCOMED are intrinsically supported by the data in patients,
we consider that our approach can help to shorten the process of
identiﬁcation of both cancer-driving mechanisms and therapeutic
targets valid in human beings.
RESULTS
In order to illustrate the usage of the proposed methodology, we
chose breast cancer because of its relevance to public health and
the abundance of publicly available data sets with both tumor
transcriptomics and patient clinical follow-up data, which is
required for use of the method. We applied SURCOMED to two
independent data sets for discovery and validation purposes,
with 1,971 and 1,809 breast cancer patients respectively. The
‘discovery’ data set was used to search for processes or pathways
potentially relevant for patient survival after tumor resection. To
this end and according to our proposed strategy, the ﬁrst step is
to identify genome-wide combinations of marker genes with an
optimal survival separation between patients with and without
these markers. This search is not biased by prior knowledge and,
in principle any gene is equally eligible. It is important to note that
in this work we deﬁne a survival marker gene not only by the gene
itself but also by the expression level (either ‘high’ or ‘low’) within
the context of the population of patients (see Materials and
Methods). The genome-wide search was performed on a group of
11,849 genes shared by the microarray platforms used in both the
‘discovery’ and the ‘validation’ data sets. The complete lists of
genes are included in Supplementary Table S1.
Identiﬁcation of optimized combinations of survival marker from
genome-wide search
In order to perform this search, we used the 1,971 patients of the
‘discovery’ data set, and looked for combinations of 4 survival
marker genes. Indeed, in a preliminary analysis, we observed that
the survival separations based on 4 genes performed favorably
Figure 1. Two strategies to identify relevant cancer-driving mechan-
isms. In a ‘bottom–up’ or hypothesis-driven approach, gene
expression proﬁles associated with a biological phenotype or
deregulated pathway are ﬁrst identiﬁed and then subsequently
correlated with the clinical outcome. In a ‘top–down’ approach,
cohorts of patients with known clinical outcomes are characterized
and compared in order to identify biological mechanisms associated
with prognosis without any a priori biological assumption.
Figure 2. SURCOMED ﬂow chart. SURCOMED takes as input tumor
transcriptomics data and the clinical information from the corre-
sponding patients, in particular, the survival time. The output
consists of biological processes, molecular mechanisms or pathways
up- or downregulated between groups of patients with long and
short survival time. These groups of patients are deﬁned by sets of
marker genes identiﬁed by iterative survival analysis using an
evolutionary algorithm. The iterative survival analysis can be
described in 3 steps: (1) Generate combinations of marker genes.
At the ﬁrst iteration, the combinations are totally random; in
posterior iterations, the generation of new combinations is based on
the probability distribution of survival marker genes within the best
combinations in the previous iteration; (2) Evaluate combinations of
marker genes. This evaluation is based on the difference between
the restricted mean survival time between the pro- and anti-survival
groups; and (3) Select the best combinations of marker genes. Once
the iterative survival analysis ﬁnishes, the resulting optimized
combinations of marker genes are used to split the population of
patients into pro- and anti-survival groups. A gene set enrichment
analysis (GSEA) is subsequently applied in order to identify
molecular mechanisms, biological processes or pathways for which
their constituent genes exhibit concordant differences between
pro- and anti-survival groups. This allows the identiﬁcation of
deregulated mechanisms between pro- and anti-survival patients.
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with respect to combinations of smaller and greater number of
marker genes in terms of survival separation, but it is worth noting
here that the method can be applied to any combination size
(see Discussion). After the application of SURCOMED, we selected
among 15,000 combinations evaluated by the algorithm
(see Materials and Methods) the top 50 for further analysis, 49
of them with a statistically signiﬁcant survival separation
(Benjamini and Hochberg adjusted P valueo0.05). Only the
combination CENPF::low HTR2C::high HTR4::high CDHA5::high
obtained a non-signiﬁcant adjusted P value. The calculation of
adjusted P values is needed because, unlike the classical survival
analysis of a single hypothesis, which implies a strong and simple
statistical model, here we are considering multiple hypotheses
and the resulting P values have to be adjusted according to the
number of hypotheses tested.
These combinations were compared with respect to a popula-
tion of randomly selected combinations (n= 1,000) using a t-test,
and all of them were found signiﬁcantly different from the survival
values of the random population (P value of the t-testo0.05). The
results of the t-test are included in Supplementary Table S2. In
summary, taking together the survival analysis of each combina-
tion and the comparison with respect to population of combina-
tions randomly selected, we concluded that all selected
combinations exhibited not only a statistically signiﬁcant survival
separation but also that the magnitude of this separation is very
unlikely to be obtained by chance.
The top 50 combinations of survival markers (Table 1) were
identiﬁed after the iterative optimization (maximization) of the
survival separation between groups of patients with opposite
expression proﬁle for a given combination. In other words,
patients with a proﬁle for genes A, B, C and D of, for example,
A::high, B::low, C::high and D::high are compared (in survival terms)
with respect to patients with A::low, B::high, C::low, and D::low (see
Materials and Methods section for more details). After several
iterations of the algorithm with the evaluation of multiple
combinations and selection of the best ones, a ﬁnal optimized
set of combinations of survival markers is obtained. Details of this
optimization are included in the Materials and Methods section.
Validation of the identiﬁed combinations of survival marker genes
in an independent data set
As we showed, it is very unlikely that combinations of
genes randomly selected constitute a good combination of
survival markers, but it is possible that some combinations
of survival markers identiﬁed in our 'discovery' data set cannot
be extrapolated to other data sets. To explore this possibility, the
identiﬁed signatures were validated using an independent
'validation' data set with 1,809 breast cancer patients. Of them,
62% obtained a statistically signiﬁcant survival separation and
similar behavior to that observed in the ‘discovery’ data set.
Signatures without statistical support in the ‘validation’ analysis
can be considered as over-ﬁtted to the ‘discovery’ data set or to
correspond to survival signatures missing in the ‘validation’ data
set. The survival curves of DPT::high RSRC1::low SLC2A6::low STX8::
high and SERPINA7::high SLC7A6::low SPG11::low STX8::high are
shown in Figure 3 as examples of identiﬁed validated and
non-validated signatures respectively. Complete results compar-
ing the identiﬁed signatures in both ‘discovery’ and ‘validation’
data sets are included in Supplementary Table S3.
Identiﬁcation of pathways, biological processes or molecular
mechanisms associated with survival
In order to identify mechanisms of action potentially involved in
the observed survival effect, for each of the 50 selected
combination of markers we applied a gene set enrichment
analysis (GSEA), a computational method that determines whether
an a priori deﬁned set of genes shows statistically signiﬁcant,
concordant differences in expression between two biological
phenotypes.8,9 These predeﬁned gene sets consist of groups of
genes with the same functional annotation (for example,
biological processes or pathways) in databases such as GO or
KEGG, so they are constant, whereas, for each combination, the
biological phenotypes are different and deﬁned by the combina-
tion of survival marker genes, which split the population of
patients into pro- and anti-survival phenotypes. The results of the
GSEA allow not only to detect concordant differences in gene
expression between pro- and anti-survival phenotypes but also to
determine the sign of the difference or, in other words, whether a
Table 1. Top 50 combinations of survival markers identiﬁed by
SURCOMED
Combinations of survival markers
(1–25)
Combinations of survival markers
(25–50)
ABCG1::high HSD17B1::high CDCP1::low ETV2::low
RNASEH2A::low RPS9::high HMGCR::low PLA2G2F::high
ACADVL::high FGL2::high CDCP1::low GSTM2::high
S100A9::low SNX1::high PLOD2::low YBX2::low
ACOXL::low GSTM2::high CDCP1::low MYO7B::high
PLOD2::low YBX2::low TMEM156::high TNFRSF4::low
ACOXL::low RSRC1::low CENPF::low HTR2C::high
SLC2A6::low STX8::high HTR4::high CDHA5::high
ACTB::low CRIM1::high COL16A1::high DERL1::low
CYP19A1::low GALNT12::high TESK1::low ZNF177::high
ADCY3::high MT1M::high COL16A1::high FIBP::low
PTTG1::low TP53BP2::low IL21R::high PSMD3::low
ADCY3::high NHLH1::high COPZ1::low EGR1::high
SERPINE1::low SORL1::high HINFP::high KIF20B::low
ANXA2::low CENPF::low CSH2::low GSTT2::high
HTR4::high PCDHA5::high KL::high ZNF277::high
ANXA2::low CENPF::low CYFIP2::high LUZP4::low
PCDHA5::high TMEM156::high PHLPP2::low WDR19::high
ANXA2::low MYO7B::high DCAF7::low FAS::low
TMEM156::high TNFRSF4::low PLAC8::high PRMT3::low
AQP4::high COPZ1::low DERL1::low DPT::high
HINFP::high KIF20B::low TESK1::low ZNF177::high
AQP4::high MT1M::high DLEC1::high ETV2::low
PTTG1::low TP53BP2::low HMGCR::low PLA2G2F::high
ATPAF2::high BMS1::low DLEC1::high FIBP::low
FBXL14::high INSR::low HINFP::high TNFRSF4::low
ATXN3::low SLC6A6::low DPT::high RSRC1::low
WDR60::high ZNF16::high SLC2A6::low STX8::high
B4GALT7::low BUB1::low EGR1::high NHLH1::high
C10orf95::low CCL3L1::low SERPINE1::low SORL1::high
BLM::low CXCL3::low ELK4::low GUCY1B2::low
NUP133::low TROAP::low MBNL1::high PDCD6IP::high
BMPR1B::high FIBP::low ETV2::low PSMD3::low
IL21R::high PSMD3::low HMGCR::low MYO7B::high
BMPR1B::high ITM2A::high GCLC::high MX2::low
OAS3::low RAB30::high NQO1::low SPG20::high
BRD7::low LRPPRC::low GPX4::high MRPS28::high
SH2B3::low TRIB3::low MSR1::low TROAP::low
C16orf70::low KCTD2::high HTR2C::high ITM2A::high
PHLDA2::low SPAST::high OAS3::low RAB30::high
C17orf53::low HNRNPA3P1::high LILRA3::low NES::low
PTPN1::low TRIM45::high RRAGA::high SGCE::high
CANT1::low CXCL9::low MVD::low RNASEH2A::low
PECR::low PSME3::high SLC2A6::high STK17B::low
CATSPER2P1::high HIST1H2BF::low NDUFA4L2::low PDK1::low
RPS7::low SETD1B::low RGS5::high UBE2L3::high
CBX8::low FGF17::high NPY2R::high PIGV::high
FIS1::high PRKAR1B::low RPL10L::low ST5::high
CCL20::low PDLIM1::high SERPINA7::high SLC7A6::low
STX12::high WDR19::high SPG11::high TMEM186::low
SURCOMED was applied to a data set of 1,971 breast cancer patients.
Combinations with the greatest difference in restricted mean survival time
(RMST) between pro- and anti-survival groups of patients are shown in
the table.
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given gene set corresponding to a mechanism of action
(biological process, pathway or molecular mechanism) is up- or
down- regulated in the phenotypes under consideration. This
analysis is intended to detect not only those mechanisms that are
more common or frequent but also those that are restricted to a
reduced subset of the population of patients.
Figure 4 shows the dendrogram of survival combinations
organized by hierarchical clustering based on the vector of all
biological mechanisms found signiﬁcant in any of the combina-
tions by GSEA, and a heatmap representing the activity of the
biological mechanisms for each survival combination. The
exploration of the heatmap in Figure 4 shows both biological
mechanisms consistently up- or down- regulated across survival
combinations and others that are only up- or down- regulated in a
fraction of the survival combinations or even with opposite
regulation in different groups of pro-survival patients.
Table 2 shows the most frequent up- and down- regulated
biological mechanisms across the top 50 combinations of survival
markers (complete results in Supplementary Table S4). Table 3
shows 20 frequent biological mechanisms that are either up- or
downregulated depending of the survival combinations of
markers. Some of these mechanisms are usually associated with
a better disease progression, such as the up-regulation of 'T cell
activation' or 'T cell differentiation'. However, we found that for
some combinations of survival markers, or, in other words, for
some subgroups of patients with high survival, these mechanisms
are clearly downregulated. Elucidation of the circumstances of
such dual mechanisms is a matter for future work.
Among the most frequent up-regulated biological mechanisms,
it is worth highlighting 'Nuclear signaling by ERBB4' (HER4),
'HNF3A (FOXA1) pathway' and 'Transforming growth factor beta
(TGFB) signaling pathway', which appeared in 70, 60, and 50% of
the survival combinations of markers, respectively. These three
pathways are particularly interesting because they have been
reported to be both positively and negatively associated with a
favorable clinical outcome, and their dual behavior has been
proposed to be associated with speciﬁc subgroups of the
population of patients.
In particular, ERBB4 has been suggested to have both onco-
genic and tumor suppressive functions.10,11 According to some
reports, high expression levels of ERBB4 are associated
with favorable clinical outcome.12,13 However, other reports
have suggested an association between ERBB4 and a poor
prognosis.14,15 Furthermore, it has been reported that, in breast
cancer, ERBB4 is associated with favorable prognosis in ER-positive
patients, but not in ER-negative patients,16 which may explain the
dual effect due to the stratiﬁcation of different populations of
patients.
HNF3A is a downstream target of GATA3 in the mammary
gland, and it is highly correlated with low-grade morphology and
improved survival in ER-negative breast cancer.17 Interestingly and
similarly to the ERBB4 case, in ER-positive breast cancer HNF3A it
might be associated with poor clinical outcomes and treatment
resistance due to the rapid reprogramming of the ERa signaling.18
Similarly to ERBB4 and HNF3A, TGFB has been proposed to be
both positively and negatively associated with the clinical
Figure 3. Survival analysis of identiﬁed signatures in both 'discovery' and 'validation' data sets. (a) Example of validated signature. The survival
signature DPT::high RSRC1::low SLC2A6::low STX8::high exhibited a statistically signiﬁcant survival separation in both ‘discovery’ and
‘validation’ data sets (P valueo0.05). (b) Example of non-validated signature. The survival signature SERPINA7::high SLC7A6::low SPG11::low
STX8::high was identiﬁed in the ‘discovery’ data set, but no signiﬁcance difference in survival was found in the ‘validation’ data set.
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outcomes. In this case, in early stages of breast cancer, TGFB
shows tumor suppressive effects with the inhibition of the
epithelial cell cycle progression and promotion of apoptosis.
However, in late stages it has been associated with an increased
tumor progression, higher cell motility, invasiveness and
metastasis.19
Given that all of our previously identiﬁed combinations of
survival markers exhibited either the up-regulation of these three
pathways or non-signiﬁcant deregulation, we decided to investi-
gate their dual effect by performing three new analyses in which
the search for combinations of survival markers was constrained
by the downregulation of ERBB4, HNF3A, and TGFB1 genes
correspondingly. In all of these three new searches, SURCOMED
managed to ﬁnd several combinations of survival markers
statistically signiﬁcant (P valueo0.05) and remarkable survival
effect (see examples in Figure 5).
Concerning the top downregulated biological mechanisms, it is
worth noting that some of them were in most of the 50 selected
survival combinations, as for example the downregulation of
functional categories related to cell division and regulation of
mitosis. Among the most frequent downregulated we also found
the 'ATR pathway' in 82% of the combinations, which is involved
in the regulation of the DNA damage response. The DNA repair
pathway, when less efﬁcient, is associated with better survival
because it induces the formation of neoantigens. Highly selective
small molecule inhibitors of ATR are currently in clinical
development for cancer therapy.20
These results highlight the capacity of SURCOMED to identify
relevant biological mechanisms that become potential targets for
novel therapies and illustrate the utility of SURCOMED to
investigate complex paradox behavior of biological mechanisms
involved in survival.
It is worth noting that there exist other methods potentially useful
to detect biological mechanisms differentially regulated between
groups of samples or patients once they are deﬁned by the detected
combination of genes. To illustrate an alternative approach to GSEA,
we performed a second analysis where a list of genes differentially
expressed between pro- and anti-survival groups of patients is
analyzed to ﬁnd statistical overrepresentation of functional annota-
tion terms. Complete results of this analysis and R scripts are
provided as Supplementary Information (Supplementary Table S5
and Supplementary Data S2 respectively).
Interestingly, the alternative approach using differential
expression analysis between pro- and anti-survival groups of
patients and statistical overrepresentation of functional annota-
tion terms, instead of GSEA, also detected ERBB signaling pathway
(GO:0038127), TGFB signaling pathway (KEGG: hsa04350) and
several terms associated to response to DNA damage
Figure 4. Heatmap representing molecular mechanisms, biological processes, and pathways identiﬁed by SURCOMED in association with 50
different combinations of survival marker genes. Within the heatmap, if a biological mechanism is up- or downregulated, it is represented in
red and blue respectively (white if it is not statistically signiﬁcant). Some of the identiﬁed biological mechanisms are consistently up- or
downregulated in most of the combinations, whereas others appeared only in some of the combinations. Interestingly, there exist some
biological mechanisms with opposite regulation in different groups of pro-survival patients, which reﬂects the dual effect of some
mechanisms, such as the 'Nuclear signaling by ERBB4' (HER4), 'HNF3A (FOXA1) pathway' and 'Transforming growth factor beta (TGFB)
signaling pathway'.
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(GO:0000077, GO:1902402 and GO:1902230) as statistically
signiﬁcant.
The three examples of paradoxical dual effects emphasize the
necessity of novel methodology such as the one proposed in this
work in order to disentangle the complexity of cancer mechan-
isms. It seems clear that different subgroups of patients behave
differently and that a single combination of survival markers is not
sufﬁcient to capture the variety of biological mechanisms under-
lying disease progression and survival.
Table 2. Top 40 survival mechanisms found by SURCOMED in 1,791
breast cancer patients
Biological processes, molecular mechanisms and
pathways
Occurrences State
Reactome nuclear signaling by ERBB4 35 Up
Amine binding 31 Up
Auxiliary transport protein activity 31 Up
Neuron differentiation 31 Up
Transmembrane receptor protein serine
threonine kinase signaling pathway
31 Up
Axonogenesis 30 Up
PID ERA genomic pathway 30 Up
PID HNF3A pathway 30 Up
Reactome G alpha S signaling events 30 Up
Ligand dependent nuclear receptor activity 29 Up
Neurite development 29 Up
Reactome phase1 functionalization of
compounds
29 Up
Cellular morphogenesis during differentiation 27 Up
Channel regulator activity 27 Up
Kegg drug metabolism cytochrome P450 27 Up
Pattern speciﬁcation process 27 Up
Biocarta BAD pathway 26 Up
Neurogenesis 26 Up
Reactome nuclear receptor transcription
pathway
26 Up
Transforming growth factor beta receptor
signaling pathway
25 Up
Reactome kinesins 44 Down
Regulation of mitosis 44 Down
M phase 43 Down
Reactome cell cycle checkpoints 43 Down
Transferase activity transferring phosphorus
containing groups
43 Down
M phase of mitotic cell cycle 42 Down
Mitosis 42 Down
Organelle organization and biogenesis 42 Down
Reactome assembly of the pre replicative
complex
42 Down
Reactome cell cycle 42 Down
Reactome DNA replication 42 Down
Reactome M-G1 transition 42 Down
Reactome mitotic M–M–G1 phases 42 Down
Reactome regulation of mitotic cell cycle 42 Down
Cell cycle process 41 Down
Chromosome segregation 41 Down
PID ATR pathway 41 Down
Reactome APC C CDH1 mediated degradation
of CDC20 and other APC C CDH1 targeted
proteins in late mitosis early G1
41 Down
Reactome cell cycle mitotic 41 Down
Cell cycle GO 0007049 40 Down
The table shows the most frequent up- and downregulated biological
mechanisms across the top 50 combinations of survival markers.
Highlighted in italic, 'ATR pathway', 'Nuclear signaling by ERBB4' (HER4),
'HNF3A (FOXA1) pathway', and 'Transforming growth factor beta (TGFB)
signaling pathway', appeared in 82, 70, 60 and 50% of the survival
combinations of markers, respectively. They constitute examples of well-
known cancer-driving mechanisms.
Table 3. 20 survival mechanisms that can be either up- or
downregulated
Biological mechanism Up Down Total
Reactome class A1 rhodopsin like receptors 8 8 16
Homeostatic process 7 8 15
Reactome G alpha I signaling events 8 7 15
Reactome gpcr ligand binding 11 7 18
Regulation of developmental process 6 9 15
Kegg cytokine cytokine receptor interaction 6 8 14
Negative regulation of developmental process 6 6 12
Regulation of signal transduction 6 6 12
Regulation of multicellular organismal process 7 6 13
Reactome peptide ligand binding receptors 10 6 16
Regulation of biological quality 11 6 17
Positive regulation of immune response 5 12 17
T cell activation 5 12 17
Reactome hemostasis 5 11 16
Regulation of cell proliferation 5 11 16
T cell differentiation 5 10 15
Biocarta NKT pathway 5 9 14
Cytokine activity 5 8 13
Cytokine binding 5 8 13
Kegg regulation of actin cytoskeleton 5 8 13
The table shows 20 frequent biological mechanisms across combinations
of survival markers that can be either up- or downregulated depending of
the particular case.
Figure 5. Combinations of survival markers found by SURCOMED
with forced downregulation of ERBB4, HNF3A (FOXA1) and TGFB1.
All combinations exhibited a clear separation between pro- and
anti-survival groups and a P value o0.05.
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Impact of the data set in the identiﬁcation of biological
mechanisms
In order to investigate the impact of the data set in the
identiﬁcation of biological mechanisms, we applied SURCOMED
to the 'validation' data set (acting now as 'discovery') and
compared the results from both data sets. Among the 1516
signiﬁcant biological mechanism identiﬁed in this second analysis,
1417 were common to those obtained from the 'discovery' data
set. Concerning the top 40 biological mechanisms identiﬁed in the
'discovery' data set, 36 of them were also identiﬁed in the
'validation' data set. Some of them were very similar in frequency,
such as the 'Nuclear receptor transcription pathway' present in 52
and 54% of the signatures in 'discovery' and 'validation' data set
respectively, whereas others differ in frequency, such as 'Nuclear
signaling by ERBB4', 'ATR pathway' or 'Transmembrane receptor
protein serine threonine kinase signaling pathway' (complete
results are included in Supplementary Table S6). Regardless of the
differences in frequency, which may reﬂect a different population
structure or some kind of bias in the patient recruitment for the
study, these results stress the robustness of the analysis across
different data sets.
Stratiﬁcation of patients based on multiple combinations of
survival markers
Despite the methodology proposed here is mainly intended to
assist in the identiﬁcation of cancer-driving mechanisms of action,
it can be also applied to case classiﬁcation. The stratiﬁcation of the
population of patients is the other side of the coin of personalized
therapy; it allows us to determine groups of patients for which
targeting a speciﬁc cancer-driving mechanism is suitable, once
such mechanisms are identiﬁed and validated.
To illustrate this idea, the 50 selected combinations of survival
marker genes were used to construct a matrix patient-combina-
tion, where, there exists a Boolean vector of 50 elements for each
patient that take values of '1' if the combination of survival
markers is present in the patient and '0' if it is absent
(Supplementary Table S7). These vectors allowed us to compare
and cluster patients in different groups based on the entire
collection of 50 combinations of survival markers at the same
time. The results of this analysis were summarized in a
dendrogram of patients organized by hierarchical clustering
based on the occurrence of the 50 combinations of survival
markers, and the corresponding heatmap precisely representing
these occurrences (Figure 6).
It is also worth noting that the construction of such a matrix also
allowed us to explore the co-occurrence of different combinations
of survival markers, ranging from 0 up to 20 combinations in the
same patient (Supplementary Table S8). Despite some of these
signatures possibly corresponding to different markers of the
same underlying biological mechanisms, which is perfectly
possible as it is shown in Figure 4, others may produce an
additive or synergistic survival effect. To illustrate this idea, we
performed a survival analysis (Figure 7) comparing the two tails
(~5% or 100 patients) of the patients list ranked based on number
of combinations of survival markers present in a given patient. In
Figure 6. Heatmap representing the occurrence of 50 combinations of survival markers found by SURCOMED in breast cancer patients. The
dendrogram on the top corresponds to the hierarchical clustering of patients based on these combinations. This ﬁgure illustrates that
multiple survival signatures can be used to structure the population of patients and potentially to classify new patients in speciﬁc groups. The
ﬁgure also shows that different combinations of survival markers can coexist in the same patient, either because they are associated with the
same underlying biological mechanism or because multiple mechanisms are present in the same patient.
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one of the tails, we have patients with only 1 survival signature,
whereas the other tail combinations of survival markers range
between 10 and 20 per patient. Results showed a clear survival
separation of these two groups of patients, which supports the
idea that survival can operate through different and sometimes
independent mechanisms with additive or synergistic effect when
they are together in the same patient.
The list of coexisting combinations of survival markers for each
patient is included in Supplementary Table S8. The complete
deconvolution of the underlying dependent and independent
survival mechanisms is beyond the scope of this article and a
matter of future work.
DISCUSSION
In this work, we propose a novel method, designated SURCOMED,
in which patient survival is the starting point that guides the
identiﬁcation of molecular mechanisms of action involved in
cancer progression. This method conceptually differs from the
regular use of the Kaplan–Meier estimate to validate or support a
given hypothesis and can be considered both an alternative and
complementary to ‘bottom–up’ approaches to elucidate cancer
progression mechanisms.
The main strength of SURCOMED is that it is not biased by prior
knowledge; we report here that SURCOMED can be applied in a
blind manner to discover biological mechanisms involved in
disease progression, which can lead to unexpected ﬁndings. The
blindfolded application of SURCOMED allowed us to identify
several deregulated pathways well known as involved in breast
cancer progression, such as the up- and downregulation of ERBB4,
HNF3A and TGFB and ATR pathways, respectively. In addition,
SURCOMED can also be applied under certain constrains in order
to investigate speciﬁc questions. We illustrated this capability in
three speciﬁc cases by searching for combinations of survival
markers accompanying the downregulation of ERBB4, HNF3A and
TGFB genes. In the three cases, SURCOMED managed to ﬁnd
combinations of survival markers under these constraints, which is
consistent with the previously reported dual effect of these genes
on disease progression.
The main limitation of SURCOMED is that it operates only on
existing expression proﬁles within the population of patients, and
only these existing expression proﬁles can be compared and
selected as optimal combinations of survival markers; there is no
prediction or projection to anticipate the behavior of expression
proﬁles that are not already present in the population of patients.
This means that a greater variety of comparisons can be
performed on large, heterogeneous data sets, leading to better
rank combinations of survival markers, whereas results will be
more limited for smaller, more homogeneous data sets. Similarly,
the way in which SURCOMED intersects groups of patients to
calculate the combined survival effect makes this calculation only
possible for large data sets, and this problem is exacerbated as the
number of genes in the combination is increased. We empirically
observed that, for combinations of 4 genes, SURCOMED performs
reasonably well with data sets as small as 100 patients randomly
selected from larger populations, and with results consistent with
those obtained using greater number patients.
We have shown that SURCOMED can be used for patient
stratiﬁcation based on multiple combinations of survival signa-
tures, which suggest potential translational applications. However,
we believe that the capacity to classify a case in a predeﬁned
group is more useful if the group is well characterized in terms of
biological mechanisms, which ultimately would lead to the
development of more personalized therapies.
Moreover, it sounds reasonable to classify patients based on the
solvency of the different biological mechanisms underlying
disease progression, and treat them according to their special
demands. It is precisely this mechanism-centered vision of patient
classiﬁcation that is the main motivation of this work, and the
identiﬁcation of combinations of genes that make the difference
at the mechanism level (summarized as the clinical outcome in
terms of patient survival) is the core of the proposed methodol-
ogy. The deconvolution of the contributing biological mechanisms
to cancer progression is by no means simple, but we consider that
this work constitutes a step forward in this direction. Of course, a
ﬁnal mechanism-centered patient classiﬁcation would require the
experimental validation of the identiﬁed biological mechanisms,
which constitutes a monumental challenge beyond the scope of
this work and motive of future directions.
Finally, it is worth mentioning that, in this study, we have used
breast cancer as an illustrative example, but SURCOMED is by no
means restricted to this disease, and we plan to apply SURCOMED
to a variety of solid tumors and other diseases or biological
processes beyond cancer in the coming years.
MATERIALS AND METHODS
Iterative survival analysis: search of optimal combinations of
survival marker genes
The algorithm takes as the input a collection of transcriptomics data
derived from resected tumors and the clinical information of the
corresponding patients, more speciﬁcally, the survival time. As the output,
the algorithm delivers one or several combinations of highly or lowly
expressed genes with an optimized survival separation associated with
their expression levels. The exhaustive search of optimal combinations of
marker genes is a huge combinatorial problem that we addressed with a
strategy that explores the vast search space by iterative optimization of the
clinical outcome, i.e., the observed survival effect. To this end, the
algorithm uses an evolutionary optimization based on an estimation
of distribution algorithm, a well-known strategy commonly used in
bioinformatics.21
During the search process, there are several rounds of optimization or
iterations (we used 50 iterations in this work) in which new combinations
of genes are generated based on the probability distribution of gene states
calculated in the subset of combinations with the best survival separation
in the previous iteration. The optimization continues until the maximum
number of iterations (deﬁned by the user) is reached. One or several
Figure 7. Survival analysis comparing patients with multiple and
single survival signatures. The blue curve corresponds to 100
patients with a number of combinations of survival markers (survival
signatures) ranging between 10 and 20, whereas the red curve
corresponds to 100 patients with only 1 signature. Results showed a
clear separation between the two curves, with a P value= 1.16e− 06,
which supports the presence of multiple and independent under-
lying mechanisms with an additive or synergistic effect when they
coexist in the same patient.
Reversing cancer survival analysis
I Crespo et al
8
npj Systems Biology and Applications (2016) 16037 Published in partnership with the Systems Biology Institute
combinations with an optimized survival separation constitute the ﬁnal
output.
The algorithm for the iterative search of combinations of marker genes
can be described in 3 steps (Figure 2)—(1) generate combinations of
marker genes; (2) evaluate combinations of marker genes; and (3) select
the best combinations of marker genes.
1. Generate combinations of marker genes. In the ﬁrst iteration, the
algorithm creates a population of combinations by random selection of
a given number of genes with their corresponding states, i.e., either
‘higher’ or ‘lower’ (see ‘Combined survival analysis’ section for details).
The speciﬁc number of genes is deﬁned by the user and is the same as
the number of marker genes in the ﬁnal optimized combinations; in the
analysis included in this work, we used combinations of four genes
because we empirically observed that the survival separations based on
four genes performed reasonably well with respect to smaller and
greater combinations, but the method is applicable to any number of
genes. In the second and later iterations, new combinations of marker
genes are selected by randomly sampling the set of genes based on the
probability distribution of genes and their corresponding expression
levels (discretized to either ‘high’ or ‘low’) within the subset of
combinations with the best survival separation in the previous iteration.
In this work, we used populations of 30 combinations and selected at
each iteration the top 15 combinations with the best survival
separation. Of note, SURCOMED allows the user to force or to censor
the presence or absence of speciﬁc gene states during the search.
2. Evaluate combinations of marker genes. The algorithm evaluates the
combined survival signature for each combination of genes by
calculating the restricted mean survival time (RMST) of two groups of
patients. The ﬁrst group corresponds to those patients who fulﬁll the
expression proﬁle deﬁned by the combination, and the second group
corresponds to the opposite expression proﬁle (see ‘Combined survival
analysis’ section). The RMST is deﬁned as the area under the curve of
the survival function, and it corresponds to the average time that
patients will survive. The difference between the RMST of the ﬁrst and
second groups constitutes the score of the combination:
Score ¼ RMSTpsurv RMSTasurv
3. Select the best combinations of marker genes. Once all combinations
have been scored and ranked, only the best combinations will be used
to calculate the probability distribution of all gene states. In this work,
we used a selection number that equals half of the population number
(n= 15). Within the subset of combinations with the best survival
separation, the algorithm calculates the probability distribution of gene
states. That means that for every selected combination, SURCOMED
calculates gene-by-gene how many patients have a ‘higher’ and a
‘lower’ expression value in the group of patients with an expression
proﬁle consistent with the combination (Figure 8). The criterion to
decide whether a given expression value is ‘higher’ or ‘lower’ is based
on the median of the expression value of the gene in the entire
population of patients. Consequently, expression values above and
below the median will be considered to be in the ‘higher’ and in the
‘lower’ group, respectively. The total number of occurrences for each
gene state will be divided by the total number of patients in the group
with an expression proﬁle consistent with the combination. These
frequencies are calculated for each gene and combination. Once all
combinations are calculated, SURCOMED computes the average
frequency across combinations for each gene. The resulting frequency
will become the weight for each gene state. The greater the weight, the
higher the probability that the gene in a given state is present when
generating the next population of combinations. To sample the new set
of combinations SURCOMED uses the R function sample() with the
vector of average frequencies as argument (prob argument).
In this work, we ran SURCOMED 10 times with 50 iterations of the
algorithm and collected the top 5 combinations from each run, which
resulted in the selected 50 combinations that we used for further analysis.
Given that at each iteration of the algorithm 30 combinations were
evaluated, a total of 15,000 combinations were assessed across runs and
iterations.
It is worth mentioning that we decided to work with a population size of
30 combinations and 50 iterations after some preliminary tests. The
optimization may be beneﬁted from greater population sizes but with a
computational time cost. We strongly suggest users planning to apply
SURCOMED to a different data set to perform some preliminary runs with
different population size and small number of iterations before the actual
analysis in order to ﬁnd a suitable conﬁguration of the algorithm, which
ultimately depends on the underlying structure of the population of
patients.
Implementation of the SURCOMED algorithm
The algorithm is implemented as a web application written with the
AngularJS and d3js frameworks for the front-end part and with PHP and R
on the server side. It performs three types of analysis: ﬁrst, the search for
combinations of genes; second, the test of speciﬁc combinations;
and third, results from these two previous analyses can be redirected to
investigate deregulated mechanisms between pro- and anti-survival
groups. Both intermediate and ﬁnal results can be retrieved and
downloaded or visualized online. The web-based display of the results
enables the user to explore the survival curve of the top combinations, χ2,
and P value of the log-rank test and the number of patients considered in
each speciﬁc comparison, as well as to explore the underlying mechanisms
that distinguish pro- and anti-survival groups.
The user can deﬁne the search space by providing a list of gene symbols
or probes, or by selecting a genome-wide search. Once the analysis is
complete, an email will be sent to the user with a link to the web-based
display of the results, which can be visualized or downloaded.
The analysis can also be constrained by means of two entry-boxes where
the user can introduce a list of ‘forced’ and ‘censored’ gene states that will
be taken into account during the search; ‘forced’ refers to gene states that
will always be included in any combination, whereas ‘censored’ refers to
gene states that will be systematically avoided.
We also provide R scripts for the search, and mechanisms detection,
which can be run locally from the command line without graphical
interface (Supplementary Data File S2 and http://surcomed.sourceforge.
Figure 8. Calculation of gene state frequencies in patients of a given
combination and across combinations. The frequencies of gene A in
states of 'high' and 'low' expression in the subset of patients are
deﬁned by the expression proﬁle of a given combination. These
'high' or 'low' values are assigned when the expression levels are
respectively above or below the median of the expression for this
gene in the entire population of patients. Once this frequency has
been calculated for each of the selected combinations of genes, the
average value of these frequencies across combinations are used as
weights to sample a new set of combinations. Those gene states
with higher average values across combinations have a better
chance to be selected in the new set of combinations generated in
the next iteration of the algorithm.
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net). In addition, a user’s guide is available as Supplementary Data File S3
and http://surcomed.sourceforge.net.
Combined survival analysis
In survival analysis based on the expression of a single gene, the
population of patients is divided into two groups based on a given
threshold (for example, the median of the expression values), and the
corresponding survival curves derived from these groups are compared.
The combined survival analysis is performed by subsetting from the
population of patients two groups for comparison: those patients who
fulﬁll a given expression proﬁle and those who fulﬁll the opposite proﬁle.
To this end, for each individual gene the algorithm splits the population of
patients into two groups based on the median of the expression value of
this gene in the entire population of patients. The ﬁrst group corresponds
to those patients with an expression value above the median (‘higher’); the
second group corresponds to those patients below the median (‘lower’).
Subsequently, the resulting groups of patients are intersected according to
the gene states in the combination in order to obtain the ﬁnal two groups
for the survival comparison (Figure 9). It may happen that there are
patients in the population that do not fulﬁll the combination proﬁle or the
opposite proﬁle for all of the genes; consequently, they are not taken into
account for the comparison.
All survival analyses were performed using the R package ‘Survival’
(http://cran.r-project.org/web/packages/survival/index.html). The statistical
signiﬁcance of these analyses was determined based on the log-rank test
with a critical value calculated using a χ2 with a degree of freedom equal to
1. Only analyses with a P valueo0.05 were considered as statistically
signiﬁcant and further evaluated using the RMST difference between pro-
and anti-survival groups. In the case that the survival separation is not
statistically signiﬁcant, the score of the combination is equal to 0.
It is worth noting that more stringent thresholds than the median, such
as ﬁrst and third quartiles or 10th percentile, could be potentially applied
to split the population of patients, but such thresholds would decrease the
number of patients available for the intersections and even prevent from
ﬁnding patients with an expression proﬁle consistent with the combination
under evaluation. We admit that patients right above and below the
median may be very similar, and that there is not strong evidence to
support that they have to be classiﬁed in different categories. However, as
we have shown in this work, the noise potentially included by wrong
patient classiﬁcation does not prevent the optimization algorithm from
ﬁnding groups of patients with a clear survival separation. Consequently,
for the sake of general applicability, we decided to use the median as a
general threshold, which takes advantage of all the patients in the data set.
GSEA
GSEA allows the determination of whether an a priori deﬁned set of genes
shows statistically signiﬁcant, concordant differences in expression between
pro- and anti-survival groups of patients. To this end, we used the GSEA
software8,9 and as gene sets the collections C2 and C5 from the Molecular
Signatures Database (MSigDB).9 In order to obtain the statistical signiﬁcance
for each gene set, we ran 1,000 permutations of the GSEA for each optimized
combination of marker genes with a random assignment of phenotype for
each patient (either pro- or anti-survival) and considered only those gene
sets identiﬁed with a P valueo0.05 with respect to the permutations.
Alternatively, using the SURCOMED interface users can generate and
download the ﬁles required for running the GSEA analysis locally.
Data sets
We used two different data sets in this work, namely, the ‘discovery’ and
‘validation’ sets. The ‘discovery’ data set corresponds to the collection of
patients from METABRIC (Molecular Taxonomy of Breast Cancer Interna-
tional Consortium).22 It includes microarray expression data and clinical
information from 1,971 breast cancer patients; the platform used for the
transcriptional proﬁling was Illumina HT-12 v3. The ‘validation’ data set
includes 1,809 patients. It includes microarray expression data and clinical
information from 1,809 breast cancer patients.23 The platform used was
either on HG-U133A (GPL96) or HG-U133 Plus 2.0 (GPL570).
Availability of data and materials
The discovery data set is available at the European Genome-phenome
Archive (www.ebi.ac.uk/ega). The ‘validation’ data set is publicly available
at the KM plotter repository (www.kmplot.com). The algorithm for the
iterative survival analysis was implemented as a web-based tool, which is
publicly available at http://surcomed.vital-it.ch. R scripts for the search test
of combinations, and mechanisms detection are available at http://
surcomed.sourceforge.net).
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